Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Spatial Transcriptomics Reveals a Conserved Border Niche and Etiology-Associated Immune Rewiring in Hepatocellular Carcinoma

Created on 06 Jun 2026

Authors

Bae, S., Choi, H., Hong, S. Y., Choi, Y., Lee, K. W., Na, K. J., Hong, S. K.

Abstract

Background and Aims: The tumor-stroma interface in hepatocellular carcinoma (HCC) harbors critical intercellular interactions that shape immune evasion and treatment response, yet its spatial architecture remains poorly characterized across etiologies. Whether hepatitis B virus (HBV)-related and non-B non-C (NBNC) HCC share conserved border niche features or exhibit etiology-specific microenvironment programs is unknown. We aimed to spatially resolve the tumor boundary ecosystem and identify etiology-associated signaling networks with translational relevance. Approach and Results: We performed 10x Visium spatial transcriptomics on 11 HCC specimens (7 HBV, 4 NBNC) and applied a machine-learning pipeline integrating CancerFinder and SpaceFlow to define tumor, boundary, and stromal domains. Across etiologies, the boundary zone showed a recurrent desmoplastic niche characterized by cancer-associated fibroblast, tumor-associated macrophage, and tumor endothelial cell accumulation with collagen-integrin extracellular matrix remodeling, including COL1A1-ITGA11 and COL4A1-ITGAV. Etiology-associated differences were observed in the organization of border-zone signaling programs. In representative HBV-related sections, CCL19-CCR7 signaling showed a comparatively restricted, endothelial-skewed topology, whereas representative NBNC sections showed broader inflammatory ligand-receptor networks with elevated NF-kB-associated pathway activity. Conclusions: The HCC tumor-stroma border harbors a recurrent desmoplastic niche upon which etiology-associated immune regulatory programs may be superimposed. These findings generate spatial hypotheses relevant to etiology-informed biomarker development and future therapeutic stratification.

Preprint server: bioRxiv
The authors list and abstract were imported from bioRxiv on 06 Jun 2026.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this preprint? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 20
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement